PeptidesInfo

Research area

Healthy aging research

No peptide has been shown to extend human lifespan or healthspan. Growth-hormone secretagogues raise GH/IGF-1 — a pathway that, in animal models, is associated with shorter rather than longer life when chronically elevated. GLP-1 drugs reduce cardiovascular events in high-risk adults, which is a real but specific outcome, not 'anti-aging'.

Abstract illustration of a peptide chain used as the healthy aging research hub image

Evidence map: peptides studied in this area

How grades work →
PeptideEvidence for this areaRegulatory statusWhat has been studied
SemaglutidePromising evidenceFDA-approved for this useSELECT trial showed a 20% relative reduction in major adverse cardiovascular events in adults with overweight/obesity and established CVD — a specific outcome, graded promising for "healthy aging" broadly.
Collagen peptidesPreliminary evidenceNot FDA-approvedSmall trials in older adults report modest gains in lean mass and strength with resistance training; no healthspan endpoints.
GHK-CuPreclinical evidenceNot FDA-approvedGene-expression studies suggest GHK shifts expression patterns toward those seen in younger tissue; this is a laboratory finding, not a clinical outcome.
CJC-1295Unsupported evidenceNot FDA-approvedMarketed for anti-aging via GH restoration; no human healthspan or lifespan data, and reduced GH/IGF-1 signalling is linked to longer lifespan in several animal models.
IpamorelinUnsupported evidenceNot FDA-approvedSame rationale and same absence of outcome data as CJC-1295.

Grades reflect the strength of evidence for this research area specifically. Definitions: Established, Promising, Preliminary, Preclinical, Unsupported, Conflicting.

"Anti-aging" is not an endpoint

There is no validated way to measure "aging reversal" in a person. Trials that claim it usually measure a surrogate: a hormone level, a biomarker panel, an "epigenetic clock". None of these has been shown to predict that a treated person will live longer or stay healthier. When a peptide is sold as anti-aging, the honest question is: which measurable outcome, in which trial?

The growth-hormone paradox

The most common longevity pitch for peptides is that GH declines with age, so restoring it with secretagogues (CJC-1295, ipamorelin, sermorelin) must be rejuvenating. The animal literature points the other way: mice with reduced GH/IGF-1 signalling live longer, and people with genetic GH-receptor deficiency show low rates of cancer and diabetes. Randomised trials of GH itself in older adults produce small body-composition changes and meaningful side effects. None of this proves secretagogues are harmful, but it does mean "more GH" is not a self-evidently good longevity strategy, and we grade the claim unsupported.

What is real

Semaglutide's SELECT trial is the closest thing to a healthy-aging outcome in the peptide field: fewer heart attacks, strokes and cardiovascular deaths in a high-risk population. That is a specific benefit for a specific group, and it is worth being precise about rather than inflating into "longevity".

What we track

  • Any registered human trial of a peptide with a healthspan or all-cause-mortality endpoint.
  • Long-term cancer signals for chronic GH/IGF-1 elevation.
  • Independent replication of GHK gene-expression findings in vivo.

Analyses in healthy aging research

Benefits4 min read

Peptides for Energy and Sleep: Claims Versus Trials

Better sleep and more energy are standard peptide selling points. No growth-hormone secretagogue has been tested with sleep laboratory measurement, and the one peptide with a large sleep trial works by a completely different route.

Benefits4 min read

Peptides for Muscle Growth: What the Evidence Supports

Growth-hormone peptides are sold almost entirely on muscle claims. No controlled trial has measured muscle with them. The one peptide with positive lean-mass data is the one nobody markets for it.

Benefits4 min read

Peptides for Skin: The Benefits With Human Trials Behind Them

Skin is one of the few areas where peptides have real human trials. Topical copper peptides and oral collagen both improve measurable skin properties — modestly, over weeks, in studies mostly funded by the people selling them.

Benefits8 min read

Peptide Benefits: What the Evidence Actually Supports

Peptides are credited with dozens of benefits. Some are proven in large trials, some are modest and real, and some have never been tested in a person. This is every major benefit claim, sorted by how strong the human evidence is.

Benefits5 min read

GLP-1 Benefits Beyond Weight Loss: Heart, Kidney, Liver, and Sleep

Semaglutide and tirzepatide have now shown benefits in cardiovascular events, kidney disease, liver disease, heart failure and sleep apnoea — each in its own trial, in its own population. Here is what each one actually demonstrated.

Benefits4 min read

Collagen Peptide Benefits: What to Expect, and When

Collagen peptides have more randomised human trials than any other supplement peptide. The benefits are real, small, and take 8–24 weeks to appear. Here is what each one is worth in measurable terms.

Research analysis5 min read

GLP-1 Peptides: Established Uses Versus Emerging Research

Semaglutide and tirzepatide are the best-evidenced peptides in medicine — for specific uses. We separate the approved indications with large trials from the emerging research (kidney, liver, heart failure, sleep apnoea, Alzheimer's) and the open questions about regain, muscle loss and compounded products.

Research analysis5 min read

CJC-1295 and Ipamorelin: Growth Hormone Research and Unanswered Risks

The 'CJC/ipa' stack is sold for muscle, fat loss, sleep and anti-aging. The human evidence is a handful of short hormone-level studies, two abandoned development programmes, and no outcome trials — plus a set of risks that have never been studied because the trials were never run.

Research analysis4 min read

GHK-Cu: Skin, Hair, Wound Healing, and Evidence Quality

Copper peptide GHK-Cu has decades of laboratory work, small human trials for topical skin use, and a growing injectable market with no human data. We grade each claim — skin, hair, wounds, 'gene resetting' — separately.

Research analysis4 min read

Collagen Peptides: Joint, Skin, and Recovery Evidence

Oral collagen peptides are the rare non-drug peptide product with multiple randomised trials. The effects on skin hydration, activity-related joint pain and (with training) lean mass are real but small, and most trials are industry-funded. Here is what the studies show and where the gaps are.